‘Amazing, Isn’t It?’ Long Sought Blood Test for Alzheimer’s in Reach – The New York Times

Blood tests could become used previously, allowing individuals who were beginning to have mild memory issues to find out whether they would develop Alzheimers or instead had another condition that may be less aggressive or fast-moving, Dr. Weiner said.
And, Dr. Tanzi said, in the future blood tests might be offered to people with no disability, maybe as initial screening tools to be followed with PET scans if uneasy levels of biomarkers were spotted.
“It has the promise to make early detection of the illness possible, prior to we have symptoms,” Dr. Tanzi said, something the field would only recommend for medical use if there worked methods to prevent or deal with Alzheimers.
Dr. Hansson said his laboratory was studying whether the test might anticipate dementia in individuals without any disabilities or those with mild memory problems.
The test in the JAMA study used an approach called an immunoassay to find substances that bind to antibodies. The particular assay in the study was developed by Eli Lilly and Company, which supplied materials and 3 staff members to perform the assays; the company was permitted to review the manuscript but not ban anything in it, the authors reported.
At the Alzheimers Association conference, Dr. Hansson and a co-author, Dr. Kaj Blennow, provided their findings, as did 2 other research study groups working on tau blood tests.
One test, developed by a team at Washington University in St. Louis that consisted of Dr. Randall Bateman, Dr. Suzanne Schindler and Nicolas Barthélemy, used a technique called mass spectrometry, which discovers whole molecules of tau or amyloid. In a study released on Tuesday in the Journal of Experimental Medicine, that group found that the very same form of tau in the JAMA research study, p-tau217, correlated more carefully to amyloid buildup in the brain than another form, p-tau 181, that some researchers have been concentrating on. Dr. Schindler, an assistant teacher of neurology, stated that might be because p-tau217 emerges previously in the Alzheimers illness process.